Koers Cyclacel Pharmaceuticals Inc Nasdaq
Aandelen
US23254L3069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 2,79 mln. 2,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,55 mln. | Nettowinst (verlies) 2025 * | -26 mln. -24,36 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,16
x | K/w-verhouding 2025 * |
-0,09
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 74,05% |
Recentste transcriptie over Cyclacel Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-01-02 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 83 | 01-03-06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-10,07% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |
- Beurs
- Aandelen
- Koers CYCC
- Koers